Clinical trial NCT02826473: Focused Cognitive Testing in Inpatients
Official title: Analysis of Clinical- and Cost-effectiveness of Focused Cognitive Testing in Elective Inpatients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Neurocognitive Disorders
Keywords: Dementia
Dementia screening
General Hospital
Inpatients
Lead sponsor: Luzerner Kantonsspital
Sponsor class: OTHER
Collaborators: name: Universität Luzern
First posted: 2016-07-11
Enrollment: 150
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Neurocognitive Disorder (NCD) affects over 116'000 people in Switzerland and is frequently unrecognized and underdiagnosed. Because missed and delayed diagnosis are associated with an increased burden of disease health Service Research has prompted a discussion about diagnostic guidelines and screening programs. Some argue that screening for NCD in primary care is the optimal strategy to increase recognition rates; others consider test protocols implemented into hospital admission assessments as more justified. There is no distinct recommendation due to a lack of empirical data on the benefits and harms of cognitive testing yet. This trial strives to fill this gap and provide information about the benefits, harms and the economic case of routine cognitive testing for neurocognitive disorder in high risk elective inpatients, in Switzerland.

The investigators hypothesize that, cognitive tested patients, compared with patients not cognitive tested, will have higher health-related quality of life at 12months; and lower medical health care costs at 18months.


Eligibility criteria: Inclusion Criteria:

* Elective inpatients, living in the canton of lucerne, high risk of developing a major neurocognitive disorder, living at home

Exclusion Criteria:

* Known mental disorder according to ICD-10, chapter V, excluding F32 \& F33, patients with terminal illness, patients of intensive care unit or oncology patients, no adequate vision or hearing, no ability to speak, write or to understand German, no Informant, antidementia medication

Primary outcomes:
measure: Health related quality of life (HRQoL)
timeFrame: every month during 18months
measure: Health Service Resource Utilization / Costs
timeFrame: every month during 18months
Secondary outcomes:
measure: prevalence of neurocognitive disorder
timeFrame: baseline/6months
measure: prevalence of risk factors associated with developing major neurocognitive disorder within 6 years
timeFrame: baseline/6months
Other outcomes:
measure: caregiver burden
timeFrame: every 3 months
measure: adverse events/adverse outcomes
timeFrame: between baseline and 6months
measure: comorbidities
timeFrame: baseline
measure: neuropsychiatric symptoms
timeFrame: between baseline and 6months
measure: hospital anxiety and depression
timeFrame: every 3 months
measure: severity of cognitive impairment
timeFrame: every 6 months
Locations:
city: Lucerne
country: Switzerland
facility: Cantonal Hospital of Lucerne
state: Canton Lucerne
Study officials:
affiliation: University of Lucerne,Department of Health Sciences & Health Policy
name: Stefan Boes, Prof.Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Cantonal Hospital of Lucerne
name: Thomas Nyffeler, Prof.Dr.med.
role: STUDY_CHAIR
affiliation: Cantonal Hospital of Lucerne
name: Aljoscha Benjamin, M.A. (HSG)
role: STUDY_CHAIR
References: